Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

World Brain Day draws attention to the increasing prevalence of Alzheimer's and PD in an ageing global population.

The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.